ClinicalTrials.gg
CompletedNCT02952248Updated Jan 27, 2026Results posted

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

A Phase 1 interventional study of BI 754091 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients with dose-limiting toxicities (DLTs) in patients with selected advanced solid malignancies. Safety and tolerability will be evaluated by monitoring the occurrence of adverse events (AEs), serious AEs (SAE), and laboratory parameter abnormalities, as well as changes to vital signs.

Secondary objectives are the determination of the PK profile of BI 754091 after single and multiple doses of BI 754091, and the preliminary assessment of antitumour activity.

In the dose-expansion part of the trial, the main objectives are to further assess the safety, efficacy, PK profile, and biomarkers of BI 754091 in tumours with specific tumour types and/or genetic mutations at the RP2D.

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 110 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of signed and dated, written Form (ICF) prior to any trial-specific procedures, sampling, or analyses. If a patient declines to participate in the voluntary pharmacogenetics component of the trial, he/she will not be excluded from other aspects of the trial.
  • Patients ≥18 years of age at the time of signature of the ICF
  • Phase Ia (dose-escalation)

    • patients with a confirmed diagnosis of advanced, unresectable, and/or solid tumours (any type).
    • patients who have received all therapy known to confer clinical benefit (including or anti-PDL1 therapies, if relevant), or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies. Patients with anti- PD-1 or anti-PDL1 experience must have a minimum of 60 days between the last dose of the previous anti PD-1/PD-L1 and Cycle 1 Day 1 of BI 754091 treatment.
    • Patients may agree to provide optional paired .
  • Phase Ib (dose expansion)

    • patients with a histologically confirmed diagnosis of select advanced, unresectable, and/or metastatic solid tumours with either 1) high tumor mutation excluding high microsatellite instability or 2) squamous cell cervical, anal and skin tumors, or 3) recurrent vaginal or vulvar squamous cell carcinoma.
    • All patients must have according to (RECIST) v1.1 must have at least 1 tumour lesion amenable to biopsy, and must be medically fit and willing to undergo a biopsy before first treatment and, unless clinically , after 6 weeks on therapy
    • patients who are anti-PD-1 and anti-PDL-1naïve but have failed conventional treatment (excluding anti-PD-1 treatment), or for whom no therapy of proven efficacy exists, or who are not amenable to standard therapies.
  • (ECOG) score: 0 to 1
  • of at least 12 weeks after the start of the treatment according to the Investigator's judgement
  • Females of willing to use adequate measures from the time of screening until 6 months after trial discontinuation, who are not or will not be breast feeding, and agree to have pregnancy tests prior to the start of dosing and at regular visits during the trial. Females not of childbearing potential must have evidence of such by fulfilling one of the following criteria at screening:

    • : defined as more than 50 years-of-age and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments
    • Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
    • Women under 50 years-of-age would be considered postmenopausal if they have been amenorrhoeic for at least 12 months following the cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone and luteinizing hormone levels in the postmenopausal range for the institution.
    • For women of childbearing potential using a contraceptive pill, an additional barrier method is necessary. Acceptable highly effective methods of contraception include total sexual abstinence when this is in line with the preferred and usual lifestyle of the study participant (periodic abstinence such as calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception), an intrauterine device or intrauterine hormone-releasing system, bilateral tubal ligation, and vasectomised partner (with post-vasectomy proof of absence of sperm)
  • Further inclusion criteria apply

Exclusion criteria

Exclusion criteria:

  • Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to first trial treatment or planned within 12 months after screening, e.g.,hip replacement
  • Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial
  • Previous enrolment in this trial
  • Any or anti-tumour treatment within 4 weeks or 5 half-life period (whichever is shorter) prior to the initial administration of BI 754091.
  • Presence of other active invasive cancers other than the one treated in this trial within 5 years prior to screening, with the exception of appropriately treated basal-cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or other local tumours considered cured by local treatment.
  • Untreated (es) that may be considered active. Patients with previously treated brain metastases may participate provided they are stable (i.e., without evidence of Progression of Disease by imaging for at least 4 weeks prior to the first dose of trial treatment, and any neurologic symptoms have returned to baseline), and there is no evidence of new or enlarging brain metastases
  • Inadequate organ function or bone marrow reserve as demonstrated by the following laboratory values:

    • \<1.5 x 10\^9/L (\<1500/mm3)
    • count \<100 x 10\^9/L
    • \<90 g/L (\<9 g/dL)
    • (ALT) >2.5 times the (ULN) if no demonstrable liver or >5 times ULN in the presence of liver metastases
    • Aspartate aminotransferase (AST) >2.5 times ULN if no demonstrable liver metastases or >5 times ULN in the presence of liver metastases
    • Total >1.5 times ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 x ULN or direct bilirubin >1.5 x ULN
    • Creatinine >1.5 times ULN or \<50 mL/min (measured or calculated by Chronic Kidney Disease Epidemiology () Collaboration equation); confirmation of creatinine clearance is only required when creatinine is >1.5 times ULN.
  • Any of the following cardiac criteria:

    • Mean resting interval (QTc) >470 msec
    • Any abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting , e.g., complete left bundle branch block, third degree heart block
    • Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years-of-age, or any concomitant medication known to prolong the QT interval
    • (EF) \<55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
  • History of pneumonitis within the last 5 years
  • History of severe reactions to other monoclonal Antibodies
  • doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of BI 754091
  • Active disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy
  • Known history of infection or an active or C virus infection. HIV infection is allowed for patients in cohort 6 (cervical/anal squamous) and cohort 7 (vulvar)
  • Interstitial lung disease
  • Chronic alcohol or drug abuse or any condition that, in the Investigator's opinion, makes him/her an unreliable trial subject, unlikely to complete the trial, or unable to comply with the protocol procedures.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    Phase Ia dose escalation: Cohort 1

    Low dose.

    Drug: BI 754091

  • Experimental
    Phase Ia dose escalation: Cohort 2

    Medium dose.

    Drug: BI 754091

  • Experimental
    Phase Ia dose escalation: Cohort 3

    High dose.

    Drug: BI 754091

  • Experimental
    Phase Ib dose expansion: Cohort 4

    Patients with solid tumours including NSCLC, bladder cancer, melanoma, gastric cancer, ovarian cancer, triple-negative breast cancer, and renal-cell cancer

    Drug: BI 754091

  • Experimental
    Phase Ib dose expansion: Cohort 5

    Patients with tumours with high TMB excluding those with high microsatellite instability (MSI-high)

    Drug: BI 754091

  • Experimental
    Phase Ib dose expansion: Cohort 6

    Patients with refractory squamous cell cervical, anal, and skin tumours.

    Drug: BI 754091

  • Experimental
    Phase Ib dose escalation: Cohort 7

    Patients with recurrent human papillomavirus (HPV)-positive, or HPV-negative, vaginal or vulvar squamous cell carcinoma (VSCC)

    Drug: BI 754091

Interventions

06

What researchers measure

Primary outcomes

  1. Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks)

    Number of participants experiencing dose-limiting toxicities (DLTs) graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0 observed in the first cycle (3 weeks) in order to meet the objective of assessment of the maximum tolerated dose (MTD) of ezabenlimab.

    Time frame: Up to 3 weeks.

  2. Phase Ib Dose Expansion: Number of Participants With Dose-limiting Toxicities (DLTs) During the Entire Treatment Period

    Phase Ib dose expansion: Number of participants with dose-limiting toxicities (DLTs) during the entire treatment period

    Time frame: From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.

  3. Phase Ib Dose Expansion: Confirmed Objective Response (OR), Defined as the Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 as Assessed by the Investigator

    Confirmed objective Response (OR), defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 assessed by the Investigator, where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.

    Time frame: From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.

Secondary outcomes

  1. Phase Ia Dose Escalation: Confirmed Objective Response According to RECIST v.1.1 as Assessed by the Investigator

    Confirmed OR, defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.

    Time frame: From the first administration of BI 754091 until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent, up to 511 days.

  2. Phase Ia Dose Escalation: Maximum Measured Concentration (Cmax) of Ezabenlimab in Plasma

    Maximum measured concentration (Cmax) of ezabenlimab in plasma after single or multiple dose administration of ezabenlimab. Results for cycle 1 and cycle 2 are reported.

    Time frame: 5 minutes prior to BI 754091 infusion start and 0.5, 1, 1.5, 2, 4, 7, 24, 72, 168 and 336 hours after start of BI 754091 infusion.

  3. Phase Ia Dose Escalation: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504)

    Area under the Concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) after single and multiple dose administrations of ezabenlimab. Results for cycle 1 and cycle 2 are reported.

    Time frame: 5 minutes prior to BI 754091 infusion start and 0.5, 1, 1.5, 2, 4, 7, 24, 72, 168, 336 and 504 hours after start of BI 754091 infusion.

  4. Phase Ia Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) From the Start of Treatment Until End of Treatment

    Number of participants experiencing dose-limiting toxicities (DLTs), graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0, from the start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks.

    Time frame: From first infusion of study treatment until the last infusion of study treatment plus 30 days, up to 511 days.

  5. Phase Ib Dose Expansion: Confirmed Progression-free Survival (PFS) Defined From Date of Start of Ezabenlimab to the Date of Disease Progression or Death, Whichever Was Earlier, According to RECIST v1.1 as Assessed by the Investigator

    Confirmed Progression-free survival (PFS) defined from date of start administration of BI 754091 to the date of disease progression according to RECIST v1.1 as assessed by the Investigator or death from any cause, whichever is earlier. PFS according to RECIST v1.1: For patients with 'event' as outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1 For patients with 'censored' as outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration+ 1 Median progression free survival time in months is reported.

    Time frame: From first BI 754091 infusion until disease progression or death, whichever is earlier up to 1668 days.

  6. Phase Ib Dose Expansion: Percentage of Participants With Adverse Events (AEs)

    Percentage of participants with adverse events (AEs)

    Time frame: From first infusion of study treatment until end of study treatment plus 30 days, up to 1668 days.

  7. Phase Ib Dose Expansion: Percentage of Participants With Serious Adverse Events (SAEs)

    Percentage of participants with serious adverse events (SAEs).

    Time frame: From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.

  8. Phase Ib Dose Expansion: Percentage of Participants With Clinically Relevant Abnormalities in Laboratory Evaluations

    Percentage of participants with clinically relevant abnormalities in laboratory evaluations is reported by the percentage of participants with liver enzyme elevations. Abbreviations: ALT: Alanine aminotransferase ALP: Alkaline Phosphatase AST: Aspartate aminotransferase ULN: Upper limit of normal \*: Tbili elevation must be within +/- 30 days of ALT and/or AST elevation

    Time frame: From first infusion of study treatment until end of study treatment plus 30 days, up to 1668 days.

07

Results

Posted Jan 27, 2026

Participant flow

An open-label, multicentre, phase 1 trial in patients with advanced solid tumours. Phase Ia dose escalation part consists of 3 cohorts (80, 240 and 400 mg ezabenlimab) to determine the maximum tolerated dose, followed by Phase Ib dose expansion with 4 cohorts to further evaluate safety, pharmacokinetics and efficacy of ezabenlimab.

Participant flow — Overall Study
MilestonePhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Started33330273113
Completed0000340
Not completed33330242713
Withdrew: Adverse event0001032
Withdrew: Progressive disease3332720229
Withdrew: Missed 2 cycles of treatment due to covid-190000010
Withdrew: Patient decision0001312
Withdrew: Physician decision0000100
Withdrew: Clinical progression0001000

Outcome measures

PrimaryPhase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks)

Number of participants experiencing dose-limiting toxicities (DLTs) graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0 observed in the first cycle (3 weeks) in order to meet the objective of assessment of the maximum tolerated dose (MTD) of ezabenlimab.

Time frame:
Up to 3 weeks.
Reported as:
Count of participants · Participants
Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks)
ParticipantsPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg Ezabenlimab
Phase Ia Dose Escalation: Number of Participants With Dose-limiting Toxicities (DLTs) in the First Cycle (3 Weeks)000
PrimaryPhase Ib Dose Expansion: Number of Participants With Dose-limiting Toxicities (DLTs) During the Entire Treatment Period

Phase Ib dose expansion: Number of participants with dose-limiting toxicities (DLTs) during the entire treatment period

Time frame:
From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.
Reported as:
Count of participants · Participants
Phase Ib Dose Expansion: Number of Participants With Dose-limiting Toxicities (DLTs) During the Entire Treatment Period
ParticipantsPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Phase Ib Dose Expansion: Number of Participants With Dose-limiting Toxicities (DLTs) During the Entire Treatment Period0000
PrimaryPhase Ib Dose Expansion: Confirmed Objective Response (OR), Defined as the Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 as Assessed by the Investigator

Confirmed objective Response (OR), defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 assessed by the Investigator, where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.

Time frame:
From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.
Reported as:
Count of participants · Participants
Phase Ib Dose Expansion: Confirmed Objective Response (OR), Defined as the Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 as Assessed by the Investigator
ParticipantsPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Phase Ib Dose Expansion: Confirmed Objective Response (OR), Defined as the Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) According to RECIST v1.1 as Assessed by the Investigator4462
SecondaryPhase Ia Dose Escalation: Confirmed Objective Response According to RECIST v.1.1 as Assessed by the Investigator

Confirmed OR, defined as the best overall response of confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the Investigator where the best overall response is the best time point response recorded from the first administration of BI 754091 until the earliest of disease progression according to RECIST v1.1, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent.

Time frame:
From the first administration of BI 754091 until the earliest of disease progression, death or last evaluable tumor assessment before start of subsequent anti-cancer therapy, loss to follow- up or withdrawal of consent, up to 511 days.
Reported as:
Count of participants · Participants
Phase Ia Dose Escalation: Confirmed Objective Response According to RECIST v.1.1 as Assessed by the Investigator
ParticipantsPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg Ezabenlimab
Phase Ia Dose Escalation: Confirmed Objective Response According to RECIST v.1.1 as Assessed by the Investigator010
SecondaryPhase Ia Dose Escalation: Maximum Measured Concentration (Cmax) of Ezabenlimab in Plasma

Maximum measured concentration (Cmax) of ezabenlimab in plasma after single or multiple dose administration of ezabenlimab. Results for cycle 1 and cycle 2 are reported.

Time frame:
5 minutes prior to BI 754091 infusion start and 0.5, 1, 1.5, 2, 4, 7, 24, 72, 168 and 336 hours after start of BI 754091 infusion.
Reported as:
Geometric mean · Microgram/Milliliter
Phase Ia Dose Escalation: Maximum Measured Concentration (Cmax) of Ezabenlimab in Plasma
Microgram/MilliliterPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg Ezabenlimab
Cycle 125.3 ± 32.773.7 ± 9.93128 ± 27.1
Cycle 233.3 ± 23.796.4 ± 18.3144 ± 21.9
SecondaryPhase Ia Dose Escalation: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504)

Area under the Concentration-time curve of ezabenlimab in plasma over the time interval from 0 to 504 hours (AUC0-504) after single and multiple dose administrations of ezabenlimab. Results for cycle 1 and cycle 2 are reported.

Time frame:
5 minutes prior to BI 754091 infusion start and 0.5, 1, 1.5, 2, 4, 7, 24, 72, 168, 336 and 504 hours after start of BI 754091 infusion.
Reported as:
Geometric mean · Microgram*hours/milliliter
Phase Ia Dose Escalation: Area Under the Concentration-time Curve of Ezabenlimab in Plasma Over the Time Interval From 0 to 504 Hours (AUC0-504)
Microgram*hours/milliliterPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg Ezabenlimab
Cycle 14640 ± 28.014300 ± 19.622000 ± 31.9
Cycle 26790 ± 18.118800 ± 21.528500 ± 37.1
SecondaryPhase Ia Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) From the Start of Treatment Until End of Treatment

Number of participants experiencing dose-limiting toxicities (DLTs), graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 / 5.0, from the start of treatment until end of treatment (in all cycles) as assessed approximately every 3 weeks.

Time frame:
From first infusion of study treatment until the last infusion of study treatment plus 30 days, up to 511 days.
Reported as:
Count of participants · Participants
Phase Ia Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) From the Start of Treatment Until End of Treatment
ParticipantsPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg Ezabenlimab
Phase Ia Dose Escalation: Number of Participants Experiencing Dose-limiting Toxicities (DLTs) From the Start of Treatment Until End of Treatment000
SecondaryPhase Ib Dose Expansion: Confirmed Progression-free Survival (PFS) Defined From Date of Start of Ezabenlimab to the Date of Disease Progression or Death, Whichever Was Earlier, According to RECIST v1.1 as Assessed by the Investigator

Confirmed Progression-free survival (PFS) defined from date of start administration of BI 754091 to the date of disease progression according to RECIST v1.1 as assessed by the Investigator or death from any cause, whichever is earlier. PFS according to RECIST v1.1: For patients with 'event' as outcome for PFS: \- PFS \[days\] = date of outcome - date of first treatment administration + 1 For patients with 'censored' as outcome for PFS: \- PFS (censored) \[days\] = date of outcome - date of first treatment administration+ 1 Median progression free survival time in months is reported.

Time frame:
From first BI 754091 infusion until disease progression or death, whichever is earlier up to 1668 days.
Reported as:
Median · Months
Phase Ib Dose Expansion: Confirmed Progression-free Survival (PFS) Defined From Date of Start of Ezabenlimab to the Date of Disease Progression or Death, Whichever Was Earlier, According to RECIST v1.1 as Assessed by the Investigator
MonthsPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Phase Ib Dose Expansion: Confirmed Progression-free Survival (PFS) Defined From Date of Start of Ezabenlimab to the Date of Disease Progression or Death, Whichever Was Earlier, According to RECIST v1.1 as Assessed by the Investigator1.9 (1.2 to 3.3)2.7 (1.3 to NA)2.6 (1.4 to 6.1)4.2 (1.4 to 5.5)
SecondaryPhase Ib Dose Expansion: Percentage of Participants With Adverse Events (AEs)

Percentage of participants with adverse events (AEs)

Time frame:
From first infusion of study treatment until end of study treatment plus 30 days, up to 1668 days.
Reported as:
Number · Percentage of participants
Phase Ib Dose Expansion: Percentage of Participants With Adverse Events (AEs)
Percentage of participantsPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Phase Ib Dose Expansion: Percentage of Participants With Adverse Events (AEs)96.796.396.8100.0
SecondaryPhase Ib Dose Expansion: Percentage of Participants With Serious Adverse Events (SAEs)

Percentage of participants with serious adverse events (SAEs).

Time frame:
From first infusion of study treatment until end of study treatment at the time of interim database lock plus 30 days, up to 853 days.
Reported as:
Number · Percentage of participants
Phase Ib Dose Expansion: Percentage of Participants With Serious Adverse Events (SAEs)
Percentage of participantsPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Phase Ib Dose Expansion: Percentage of Participants With Serious Adverse Events (SAEs)33.325.948.446.2
SecondaryPhase Ib Dose Expansion: Percentage of Participants With Clinically Relevant Abnormalities in Laboratory Evaluations

Percentage of participants with clinically relevant abnormalities in laboratory evaluations is reported by the percentage of participants with liver enzyme elevations. Abbreviations: ALT: Alanine aminotransferase ALP: Alkaline Phosphatase AST: Aspartate aminotransferase ULN: Upper limit of normal \*: Tbili elevation must be within +/- 30 days of ALT and/or AST elevation

Time frame:
From first infusion of study treatment until end of study treatment plus 30 days, up to 1668 days.
Reported as:
Number · Percentage of participants
Phase Ib Dose Expansion: Percentage of Participants With Clinically Relevant Abnormalities in Laboratory Evaluations
Percentage of participantsPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Maximum ALT; >= 3x ULN and <5x ULN3.33.70.00.0
Maximum AST; >= 3x ULN and <5x ULN0.011.10.07.7
Maximum AST; >= 5x ULN and <10x ULN3.30.00.00.0
Maximum Total Bilirubin; >=2x ULN0.011.13.20.0
ALT and/or AST >= 3xULN and * total bilirubin >= 2xULN0.03.70.00.0
Maximum ALP; >=3x ULN and <5x ULN3.311.13.20.0
Maximum ALP; >=5x ULN and <10x ULN0.014.83.20.0

Adverse events

Collected over All-cause Mortality: From study start until end of study, up to 2444 days. Serious and other AEs: From treatment start until end of treatment, plus 30 days of residual effect period, up to 511 days for phase Ia dose escalation and up to 1668 days for phase Ib dose expansion.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase Ia Dose Escalation: 80 mg Ezabenlimab1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Phase Ia Dose Escalation: 240 mg Ezabenlimab1/3 (33.3%)1/3 (33.3%)3/3 (100%)
Phase Ia Dose Escalation: 400 mg Ezabenlimab2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Phase Ib Dose Expansion: 240 mg Ezabenlimab, 7 Tumours16/30 (53.3%)10/30 (33.3%)27/30 (90%)
Phase Ib Dose Expansion: 240 mg Ezabenlimab, High TMB10/27 (37%)9/27 (33.3%)24/27 (88.9%)
Phase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/Skin17/31 (54.8%)16/31 (51.6%)30/31 (96.8%)
Phase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC9/13 (69.2%)6/13 (46.2%)13/13 (100%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/31/31/30/300/270/310/13
Small intestinal obstructionGastrointestinal disorders0/30/31/30/300/272/310/13
Arterial injuryInjury, poisoning and procedural complications1/30/30/30/300/270/310/13
FistulaMusculoskeletal and connective tissue disorders0/30/31/30/300/270/310/13
Foot amputationSurgical and medical procedures1/30/30/30/300/270/310/13
PneumoniaInfections and infestations0/30/30/30/300/273/310/13
SepsisInfections and infestations0/30/30/31/301/273/310/13
Infusion site extravasationGeneral disorders0/30/30/30/300/270/311/13
PyrexiaGeneral disorders0/30/30/30/300/270/311/13
OsteomyelitisInfections and infestations0/30/30/30/300/270/311/13
Most frequent other events
Showing 10 of 158
Most frequent other events
EventPhase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCC
NauseaGastrointestinal disorders0/31/32/39/305/279/318/13
FatigueGeneral disorders1/31/32/312/306/2716/315/13
Weight decreasedInvestigations0/31/32/32/302/275/311/13
Decreased appetiteMetabolism and nutrition disorders1/31/32/36/305/276/314/13
HypokalaemiaMetabolism and nutrition disorders0/31/32/32/304/275/311/13
ArthralgiaMusculoskeletal and connective tissue disorders1/30/32/35/302/276/311/13
InsomniaPsychiatric disorders2/30/30/30/301/277/312/13
CoughRespiratory, thoracic and mediastinal disorders0/32/30/36/301/278/313/13
AnaemiaBlood and lymphatic system disorders0/30/30/32/309/277/315/13
ConstipationGastrointestinal disorders1/31/31/34/303/276/315/13

Baseline characteristics

Treated Set (TS): The TS included all participants who received at least 1 dose of ezabenlimab.

Age, Continuous
Age, Continuous(Years)Phase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCCTotal
Mean57.3 ± 11.058.3 ± 23.854.7 ± 7.864.8 ± 12.665.0 ± 10.752.5 ± 13.063.5 ± 11.560.6 ± 13.2
Sex: Female, Male
Sex: Female, Male(Participants)Phase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCCTotal
Female1022516271384
Male2315114026
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCCTotal
Hispanic or Latino01013207
Not Hispanic or Latino3232922271399
Unknown or Not Reported00002204
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase Ia Dose Escalation: 80 mg EzabenlimabPhase Ia Dose Escalation: 240 mg EzabenlimabPhase Ia Dose Escalation: 400 mg EzabenlimabPhase Ib Dose Expansion: 240 mg Ezabenlimab, 7 TumoursPhase Ib Dose Expansion: 240 mg Ezabenlimab, High TMBPhase Ib Dose Expansion: 240 mg Ezabenlimab, Cervical/Anal/SkinPhase Ib Dose Expansion: 240 mg Ezabenlimab, VSCCTotal
American Indian or Alaska Native00000000
Asian00020002
Native Hawaiian or Other Pacific Islander00000000
Black or African American100252111
White2332519291293
More than one race00013004
Unknown or Not Reported00000000
08

Study locations

13 sites
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Juravinski Cancer Centre - Hamilton Health Sciences
    Hamilton, Ontario L8V 5C2, Canada
  • The Ottawa Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de l'Universite de Montreal (CHUM)
    Montreal, Quebec H2X 0A9, Canada
  • Sarah Cannon Research Institute
    London, W1G 6AD, United Kingdom
  • The Christie Hospital
    Manchester, M20 4BX, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datasharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Apr 2021, 53 months.

Results were first posted in Jan 2026, 4 years 8 months after primary completion.

Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 53 months is above that.

Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2016
First posted
Nov 2, 2016
StartActual
Nov 21, 2016
Primary completionActual
Apr 30, 2021
CompletionActual
Aug 1, 2023
Results first posted
Jan 27, 2026
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02952248
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Nov 21, 2016
Primary completion
Apr 30, 2021
Completion
Aug 1, 2023
Results posted
Jan 27, 2026
Last update
Jan 27, 2026

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezabenlimab

Start the discussion